238 related articles for article (PubMed ID: 19149761)
1. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges.
Bellail AC; Qi L; Mulligan P; Chhabra V; Hao C
Rev Recent Clin Trials; 2009 Jan; 4(1):34-41. PubMed ID: 19149761
[TBL] [Abstract][Full Text] [Related]
2. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
3. TRAIL death receptors and cancer therapeutics.
Huang Y; Sheikh MS
Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
[TBL] [Abstract][Full Text] [Related]
4. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
5. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
Cretney E; Takeda K; Smyth MJ
Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
[TBL] [Abstract][Full Text] [Related]
6. Modulation of death receptors by cancer therapeutic agents.
Elrod HA; Sun SY
Cancer Biol Ther; 2008 Feb; 7(2):163-73. PubMed ID: 18059181
[TBL] [Abstract][Full Text] [Related]
7. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
Wang S
Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of TRAIL receptor agonists in cancer treatment.
Fulda S
Eur J Clin Pharmacol; 2015 May; 71(5):525-7. PubMed ID: 25704217
[TBL] [Abstract][Full Text] [Related]
9. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
Ashkenazi A; Holland P; Eckhardt SG
J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
[TBL] [Abstract][Full Text] [Related]
11. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
12. Modulation of death receptor pathways in oncology.
de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
[TBL] [Abstract][Full Text] [Related]
13. Spatial dynamics of TRAIL death receptors in cancer cells.
Twomey JD; Kim SR; Zhao L; Bozza WP; Zhang B
Drug Resist Updat; 2015 Mar; 19():13-21. PubMed ID: 25840763
[TBL] [Abstract][Full Text] [Related]
14. Onto better TRAILs for cancer treatment.
de Miguel D; Lemke J; Anel A; Walczak H; Martinez-Lostao L
Cell Death Differ; 2016 May; 23(5):733-47. PubMed ID: 26943322
[TBL] [Abstract][Full Text] [Related]
15. TRAIL-receptor antibodies as a potential cancer treatment.
Buchsbaum DJ; Forero-Torres A; LoBuglio AF
Future Oncol; 2007 Aug; 3(4):405-9. PubMed ID: 17661715
[TBL] [Abstract][Full Text] [Related]
16. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
[TBL] [Abstract][Full Text] [Related]
17. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
18. Translating TRAIL-receptor targeting agents to the clinic.
den Hollander MW; Gietema JA; de Jong S; Walenkamp AM; Reyners AK; Oldenhuis CN; de Vries EG
Cancer Lett; 2013 May; 332(2):194-201. PubMed ID: 22531313
[TBL] [Abstract][Full Text] [Related]
19. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
20. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics.
Falschlehner C; Ganten TM; Koschny R; Schaefer U; Walczak H
Adv Exp Med Biol; 2009; 647():195-206. PubMed ID: 19760076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]